세계의 경피 흡수형 스킨 패치 시장 - 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 유통 채널별, 지역별, 부문 예측(2024-2030년)

Transdermal Skin Patches Market Trends

The global transdermal skin patches market was estimated at USD 7.82 billion in 2023 and is projected to grow at a CAGR of 5.0% from 2024 to 2030. The rising prevalence of chronic diseases such as cardiovascular disorders, diabetes, chronic pain, etc., increased consumer preference for minimally invasive treatment, the aging global population, and technological advancements in transdermal drug delivery systems have significantly boosted the market.

Transdermal patches provide a noninvasive, convenient alternative to traditional oral and injectable medications. They enhance patient compliance and minimize the gastrointestinal side effects that often accompany oral drugs. This ease of use and consistent drug release over extended periods make transdermal patches particularly attractive for managing chronic conditions.

The market is experiencing significant growth, primarily driven by the increasing prevalence of chronic diseases worldwide. According to the CDC report published in February 2024, an estimated 129 million people in the U.S. have at least 1 major chronic disease, such as cancer, heart disease, obesity, diabetes, and hypertension. Managing chronic pain typically involves regular administration of pain relief medication, which can be cumbersome with oral or injectable forms due to their side effects and the need for frequent dosing.

Transdermal patches offer a solution by providing a controlled release of medication over extended periods, which enhances patient compliance and improves therapeutic outcomes. For instance, the fentanyl transdermal patch, used for managing severe chronic pain, delivers the drug continuously for 72 hours, reducing the need for frequent dosing and maintaining steady pain relief.

Innovations in drug delivery systems, including microneedles, iontophoresis, and permeation enhancers, have significantly broadened the scope of transdermal medication delivery, accommodating large molecules and biologics. Microneedle patches create microscopic channels in the skin, enabling the administration of large molecule drugs that are otherwise difficult to deliver transdermal. A notable example is the microneedle patch for insulin delivery in diabetic patients, which offers a painless alternative to daily injections, potentially improving glycemic control. Iontophoresis, another breakthrough technology, employs a small electric charge to enhance drug penetration through the skin. For instance, IontoPatch delivers anti-inflammatory drugs to treat conditions like tendinitis and bursitis, increasing the drug's absorption and effectiveness. These advancements boost the efficiency and reliability of transdermal delivery systems and introduce new therapeutic possibilities, driving market growth and expanding the range of treatable conditions through non-invasive means.

The rising consumer preference for minimally invasive treatments significantly drives the market. Patients and healthcare providers favor these patches for reduced pain, lower infection risk, and fewer side effects than oral medications or injections. For instance, hormone replacement therapy patches Estraderm Mx Patch by Biochemie Novartis offer a steady hormone release, minimizing side effects linked to fluctuating levels seen with oral HRT. In addition, patches for smoking cessation, pain management, and neurological disorders provide a discreet and convenient drug delivery method. This non-invasive approach enhances patient comfort and compliance, boosting the market growth as awareness of these benefits spreads.

Global Transdermal Skin Patches Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global transdermal skin patches market based on type, application, distribution channel, and region:

• Type Outlook (Revenue, USD Billion, 2018 - 2030)
• Single-layer Drug-in-Adhesive
• Multi-layer Drug-in-Adhesive
• Matrix
• Other Types
• Application Outlook (Revenue, USD Billion, 2018 - 2030)
• Pain Relief
• Smoking Reduction and Cessation Aid
• Cardiovascular Disorders
• Neurological Disorders
• Hormonal Therapy
• Other Applications
• Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Billion, 2018 - 2030)
• North America

U.S.

Canada

Mexico

• Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

• Asia Pacific

Japan

China

India

South Korea

Australia

Thailand

• Latin America

Brazil

Argentina

• Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Application Outlook
  • 2.2.3. Distribution Channel Outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Transdermal Skin Patches Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
  • 3.2.3. Industry Analysis - Porter's
    • 3.2.3.1. Bargaining power of the suppliers
    • 3.2.3.2. Bargaining power of the buyers
    • 3.2.3.3. Threats of substitution
    • 3.2.3.4. Threats from new entrants
    • 3.2.3.5. Competitive rivalry
  • 3.2.4. PESTEL Analysis
    • 3.2.4.1. Political landscape
    • 3.2.4.2. Economic and Social landscape
    • 3.2.4.3. Technological landscape

Chapter 4. Transdermal Skin Patches Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Transdermal Skin Patches Market: Type Movement Analysis, 2023 & 2030 (USD Billion)
  • 4.2.1. Single-layer Drug-in-Adhesive
    • 4.2.1.1. Single-layer Drug-in-Adhesive Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.2.2. Multi-layer Drug-in-Adhesive
    • 4.2.2.1. Multi-layer Drug-in-Adhesive Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.2.3. Matrix
    • 4.2.3.1. Matrix Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.2.4. Other Types
    • 4.2.4.1. Other Types Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Transdermal Skin Patches Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Transdermal Skin Patches Market: Application Movement Analysis, 2023 & 2030 (USD Billion)
  • 5.2.1. Pain Relief
    • 5.2.1.1. Pain Relief Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.2.2. Smoking Reduction
    • 5.2.2.1. Smoking Reduction Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.2.3. Cardiovascular Disorders
    • 5.2.3.1. Cardiovascular Disorders Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.2.4. Neurological Disorders
    • 5.2.4.1. Neurological Disorders Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.2.5. Hormonal Therapy
    • 5.2.5.1. Hormonal Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.2.6. Other Applications
    • 5.2.6.1. Other Applications Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Transdermal Skin Patches Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Transdermal Skin Patches Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Billion)
  • 6.2.1. Hospital Pharmacies
    • 6.2.1.1. Hospital Pharmacies Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.2.2. Retail Pharmacies
    • 6.2.2.1. Retail Pharmacies Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.2.3. Online Pharmacies
    • 6.2.3.1. Online Pharmacies Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Transdermal Skin Patches Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Billion)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Billion)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Billion)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Billion)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Billion)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company market share analysis, 2023
  • 8.3.2. Teva Pharmaceutical Industries Ltd
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Type benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Novartis AG
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Type benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Teikoku Pharma USA Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Type benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Viatris Inc.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Type benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Johnson & Johnson
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Type benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Luye Pharma Group
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Type benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Purdue Pharma Manufacturing LP
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Type benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Henan Lingrui Pharmaceutical Ltd
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Type benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Samyang Biopharmaceuticals Corp.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Type benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Hisamitsu Pharmaceutical Co, Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Type benchmarking
    • 8.3.11.4. Strategic initiatives